NEW YORK (GenomeWeb News) – Veridex and Novartis are partnering to "encourage and facilitate" research into circulating tumor cells as potential biomarkers in metastatic prostate cancer, Veridex announced today.

As part of the deal, Veridex is supporting a prospective, single-arm, open-label study on the effect of zoledronic acid — marketed by Novartis as Zometa — on circulating tumors in patients with metastatic castration-resistant prostate cancer, or CRPC.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.